Amgen completed its acquisition of BioVex Group, Inc.
on March 4, 2011.
These archived BioVex press releases are
provided for reference only. To view press releases
regarding the acquisition, please click the link below.
A phase III study for OncoVEXGM-CSF in melanoma is ongoing
(OPTiM study).
Visit the trial site for more information.
To view current job openings at Amgen, including former BioVex sites (Woburn, MA USA and Milton Park, UK), please click on the link below.
Amgen, Thousand Oaks
Mary Klem, +1 805-447-6979 (media)
Arvind Sood, +1 805-447-1060 (investors)
Amgen Medical Information: 1-800-77-AMGEN
(1-800-772-6436)
34 Commerce Way
Woburn
MA 01801
United States
Tel: +1 781 376 4900
Fax: +1 781 933 6025
70 Milton Park
Abingdon
Oxon
OX14 4RX
United Kingdom
Tel: +44 (0)1235 441900
Fax: +44 (0)1235 441901
© 2011 Amgen Inc. All Rights Reserved | Privacy & Terms